Christine M. Fennessey

Christine M. Fennessey

Auto-generated profile, based on publicly available information

Christine M. Fennessey

AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2017 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
CFChristine M. Fennessey
Christine M. Fennessey
MPMykola Pinkevych
Mykola Pinkevych
TITaina T. Immonen
Taina T. Immonen
ARArnold Reynaldi
Arnold Reynaldi
VVVanessa Venturi
Vanessa Venturi
BKBrandon F. Keele
Brandon F. Keele
HIV and SIV infection dynamics are commonly investigated by measuring plasma viral loads. However, this total viral load value represents the sum of many individual infection events, which are difficult to independently track using conventional sequencing approaches. To overcome this challenge, we generated a genetically tagged virus stock (SIVmac239M) with a 34-base genetic barcode inserted between the vpx and vpr accessory genes of the infectious molecular clone SIVmac239. Next-generation sequencing of the virus stock identified at least 9,336 individual barcodes, or clonotypes, with an average genetic distance of 7 bases between any two barcodes. In vitro infection of rhesus CD4+ T cells and in vivo infection of rhesus macaques revealed levels of viral replication of SIVmac239M comparable to parental SIVmac239. After intravenous inoculation of 2.2x105 infectious units of SIVmac239M, an average of 1,247 barcodes were identified during acute infection in 26 infected rhesus macaques. Of the barcodes identified in the stock, at least 85.6% actively replicated in at least one animal, and on average each barcode was found in 5 monkeys. Four infected animals were treated with combination antiretroviral therapy (cART) for 82 days starting on day 6 post-infection (study 1). Plasma viremia was reduced from >106 to <15 vRNA copies/mL by the time treatment was interrupted. Virus rapidly rebounded following treatment interruption and between 87 and 136 distinct clonotypes were detected in plasma at peak rebound viremia. This study confirmed that SIVmac239M viremia could be successfully curtailed with cART, and that upon cART discontinuation, rebounding viral variants could be identified and quantified. An additional 6 animals infected with SIVmac239M were treated with cART beginning on day 4 post-infection for 305, 374, or 482 days (study 2). Upon treatment interruption, between 4 and 8 distinct viral clonotypes were detected in each animal at peak rebound viremia. The relative proportions of the rebounding viral clonotypes, spanning a range of 5 logs, were largely preserved over time for each animal. The viral growth rate during recrudescence and the relative abundance of each rebounding clonotype were used to estimate the average frequency of reactivation per animal. Using these parameters, reactivation frequencies were calculated and ranged from 0.33–0.70 events per day, likely representing reactivation from long-lived latently infected cells. The use of SIVmac239M therefore provides a powerful tool to investigate SIV latency and the frequency of viral reactivation after treatment interruption. Elucidation of HIV dynamics is essential for a thorough understanding of viral transmission, therapeutic interventions, pathogenesis, and immune evasion. The complex dynamics of reservoir establishment and viral recrudescence upon therapy removal present the primary obstacles to developing a functional cure. We sought to develop a virus model system for use in nonhuman primates that allows for the genetic discrimination of nearly 10,000 otherwise isogenic clones. This “synthetic swarm” adds a genetic component to viral dynamics where individual viral lineages can be tracked and monitored during infection. Here we utilized this model to identify the dynamics of viral reservoir establishment and rebound. We found that after 300 or more days of therapy, between 4 and 8 distinct viral lineages could be detected upon therapeutic intervention. Using the relative proportion of each distinct genetic barcoded virus and the overall viral load curve, we could estimate the time and rate of reactivation from latency. On average, we found 1 reactivation event every 2 days with reactivation of the first rebounding variant within days of therapeutic interruption. This virus model will be useful for testing various approaches to reduce the latent viral reservoir and to molecularly track viral dynamics in all stages of infection.

8 October 2020 in Blood
Verified
Journal Article
Open access
PDF file
BRBlake J. Rust
Blake J. Rust
LKLeslie S. Kean
Leslie S. Kean
LCLucrezia Colonna
Lucrezia Colonna
KBKatherine E. Brandenstein
Katherine E. Brandenstein
NPNikhita H. Poole
Nikhita H. Poole
CPChristopher W. Peterson
Christopher W. Peterson
This article has been retracted at the request of the Authors. Please see Elsevier's Article Correction, Retraction and Removal Policy (https://www.elsevier.com/locate/withdrawalpolicy). The study's authors conducted a re-evaluation of their work, after being unable to repeat the findings with a new data set. They report that upon this re-evaluation, the published flow cytometry conflicts with new CAR PCR data, thus nullifying the original hypothesis. The Editors acknowledge and appreciate the transparency of the authors for bringing this issue to the journal's attention. Authors Rust, Kean, Colonna, Obenza, Ellis, Fennessey, Keele, Jerome, Riley, Kiem, and Peterson approve of the retraction. Authors Brandenstein, Poole, Enstrom, Maldini, and Huang did not respond. A follow-up study related to this retracted paper has now been published in Blood (https://dx.doi.org/10.1182/blood.2025032142).

3 May 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
CDClaire Deleage
Claire Deleage
TITaina T. Immonen
Taina T. Immonen
CFChristine M. Fennessey
Christine M. Fennessey
ARArnold Reynaldi
Arnold Reynaldi
CRCarolyn Reid
Carolyn Reid
BKBrandon F. Keele
Brandon F. Keele
Viral dynamics and host responses to vaginal infection of SIV in nonhuman primates may identify viral vulnerabilities for HIV.

5 September 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
WYWen-Han Yu
Wen-Han Yu
DSDavid Su
David Su
JTJulia Torabi
Julia Torabi
CFChristine M. Fennessey
Christine M. Fennessey
ASAndrea Shiakolas
Andrea Shiakolas
BJBoris Julg
Boris Julg
Broadly neutralizing antibodies (bNAbs) against HIV-1 are under evaluation for both prevention and therapy. HIV-1 sequence diversity observed in most HIV-infected individuals and archived variations in critical bNAb epitopes present a major challenge for the clinical application of bNAbs, as preexistent resistant viral strains can emerge, resulting in bNAb failure to control HIV. In order to identify viral resistance in patients prior to antibody therapy and to guide the selection of effective bNAb combination regimens, we developed what we believe to be a novel Bayesian machine-learning model that uses HIV-1 envelope protein sequences and foremost approximated glycan occupancy information as variables to quantitatively predict the half-maximal inhibitory concentrations (IC50) of 126 neutralizing antibodies against a variety of cross clade viruses. We then applied this model to peripheral blood mononuclear cell–derived proviral Env sequences from 25 HIV-1–infected individuals mapping the landscape of neutralization resistance within each individual’s reservoir and determined the predicted ideal bNAb combination to achieve 100% neutralization at IC50 values <1 μg/ml. Furthermore, predicted cellular viral reservoir neutralization signatures of individuals before an analytical antiretroviral treatment interruption were consistent with the measured neutralization susceptibilities of the respective plasma rebound viruses, validating our model as a potentially novel tool to facilitate the advancement of bNAbs into the clinic.

4 January 2022 in Cell Reports
Verified
Journal Article
Open access
APAmarendra Pegu
Amarendra Pegu
LXLing Xu
Ling Xu
MDMegan E. DeMouth
Megan E. DeMouth
GFGiulia Fabozzi
Giulia Fabozzi
KMKylie March
Kylie March
JMJohn Mascola
John Mascola
Broadly neutralizing antibodies (bNAbs) represent an alternative to drug therapy for the treatment of HIV-1 infection. Immunotherapy with single bNAbs often leads to emergence of escape variants, suggesting a potential benefit of combination bNAb therapy. Here a trispecific bNAb reduces viremia 100- to 1000-fold in viremic SHIV-infected macaques. After treatment discontinuation, viremia rebounds transiently and returns to low levels, through CD8-mediated immune control. These viruses remained sensitive to the trispecific antibody, despite loss of sensitivity to one of the parental bNAbs. Similarly, the trispecific bNAb suppresses the emergence of resistance in viruses derived from HIV-1 infected subjects, in contrast to parental bNAbs. Trispecific HIV-1 antibodies therefore mediates potent antiviral activity in vivo and may minimize the potential for immune escape.

3 April 2019 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
SOSean P. O’bRien
Sean P. O’bRien
ASAdrienne E. Swanstrom
Adrienne E. Swanstrom
APAmarendra Pegu
Amarendra Pegu
SKSung-Youl Ko
Sung-Youl Ko
TITaina T. Immonen
Taina T. Immonen
BKBrandon F. Keele
Brandon F. Keele
Chimeric Simian-Human Immunodeficiency Viruses (SHIVs) are an important tool for evaluating anti-HIV Env interventions in nonhuman primate (NHP) models. However, most unadapted SHIVs do not replicate well in vivo limiting their utility. Furthermore, adaptation in vivo often negatively impacts fundamental properties of the Env, including neutralization profiles. Transmitted/founder (T/F) viruses are particularly important to study since they represent viruses that initiated primary HIV-1 infections and may have unique attributes. Here we combined in vivo competition and rational design to develop novel subtype C SHIVs containing T/F envelopes. We successfully generated 19 new, infectious subtype C SHIVs, which were tested in multiple combinatorial pools in Indian-origin rhesus macaques. Infected animals attained peak viremia within 5 weeks ranging from 103 to 107 vRNA copies/mL. Sequence analysis during primary infection revealed 7 different SHIVs replicating in 8 productively infected animals with certain clones prominent in each animal. We then generated 5 variants each of 6 SHIV clones (3 that predominated and 3 undetectable after pooled in vivo inoculations), converting a serine at Env375 to methionine, tyrosine, histidine, tryptophan or phenylalanine. Overall, most Env375 mutants replicated better in vitro and in vivo than wild type with both higher and earlier peak viremia. In 4 of these SHIV clones (with and without Env375 mutations) we also created mutations at position 281 to include serine, alanine, valine, or threonine. Some Env281 mutations imparted in vitro replication dynamics similar to mutations at 375; however, clones with both mutations did not exhibit incremental benefit. Therefore, we identified unique subtype C T/F SHIVs that replicate in rhesus macaques with improved acute phase replication kinetics without altering phenotype. In vivo competition and rational design can produce functional SHIVs with globally relevant HIV-1 Envs to add to the growing number of SHIV clones for HIV-1 research in NHPs. Nonhuman primates provide useful models for studying HIV transmission, pathogenesis and cure strategies. Due to species-specific antiviral factors, however, HIV cannot replicate in Asian macaques directly. Some chimeric viruses incorporating HIV Envelope genes in simian immunodeficiency virus (SIV) backbone can replicate to sufficient levels in Asian macaques to permit evaluation of anti-HIV interventions. Here we describe the generation of new SHIV clones unique to the field in 4 important ways. First, these clones were generated from the globally relevant HIV-1 subtype C, which is the most prevalent form of HIV globally and is found predominately in sub-Saharan Africa where the pandemic is particularly devastating but is poorly represented among SHIVs studied to date. Second, we utilized Envelope genes from viruses that established primary infection, making these clones particularly useful in transmission studies. Third, these clones were not generated by animal passage, which may alter some of the unique properties of these Envelopes. Finally, we used direct within animal competition studies and two targeted mutations to select highly replicative clones. We provide here both the discovery of new SHIV clones, and also a process to generate additional clones in the future.